Cargando…
Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with V...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912042/ https://www.ncbi.nlm.nih.gov/pubmed/33514009 http://dx.doi.org/10.3390/pharmaceutics13020171 |
_version_ | 1783656484034314240 |
---|---|
author | Ruponen, Marika Kettunen, Konsta Santiago Pires, Monica Laitinen, Riikka |
author_facet | Ruponen, Marika Kettunen, Konsta Santiago Pires, Monica Laitinen, Riikka |
author_sort | Ruponen, Marika |
collection | PubMed |
description | In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with VER, PIP and QRT were prepared by solvent evaporation, and mixtures with ARG were prepared by spray drying in 1:1 and 1:2 molar ratios. The solid-state properties of the mixtures were characterized with X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) in stability studies under different storage conditions. Simultaneous dissolution/permeation studies were conducted in side-by-side diffusion cells with a PAMPA (parallel artificial membrane permeability assay) membrane as a permeation barrier. It was observed with XRPD that ARG, VER and PIP formed co-amorphous mixtures with FUR at both molar ratios. DSC and FTIR revealed single glass transition values for the mixtures (except for FUR:VER 1:2), with the formation of intermolecular interactions between the components, especially salt formation between FUR and ARG. The co-amorphous mixtures were found to be stable for at least two months under an elevated temperature/humidity, except FUR:ARG 1:2, which was sensitive to humidity. The dissolution/permeation studies showed that only the co-amorphous FUR:ARG mixtures were able to enhance both the dissolution and permeation of FUR. Thus, it is concluded that formulating co-amorphous salts with ARG may be a promising option for poorly soluble/permeable FUR. |
format | Online Article Text |
id | pubmed-7912042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79120422021-02-28 Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs Ruponen, Marika Kettunen, Konsta Santiago Pires, Monica Laitinen, Riikka Pharmaceutics Article In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with VER, PIP and QRT were prepared by solvent evaporation, and mixtures with ARG were prepared by spray drying in 1:1 and 1:2 molar ratios. The solid-state properties of the mixtures were characterized with X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) in stability studies under different storage conditions. Simultaneous dissolution/permeation studies were conducted in side-by-side diffusion cells with a PAMPA (parallel artificial membrane permeability assay) membrane as a permeation barrier. It was observed with XRPD that ARG, VER and PIP formed co-amorphous mixtures with FUR at both molar ratios. DSC and FTIR revealed single glass transition values for the mixtures (except for FUR:VER 1:2), with the formation of intermolecular interactions between the components, especially salt formation between FUR and ARG. The co-amorphous mixtures were found to be stable for at least two months under an elevated temperature/humidity, except FUR:ARG 1:2, which was sensitive to humidity. The dissolution/permeation studies showed that only the co-amorphous FUR:ARG mixtures were able to enhance both the dissolution and permeation of FUR. Thus, it is concluded that formulating co-amorphous salts with ARG may be a promising option for poorly soluble/permeable FUR. MDPI 2021-01-27 /pmc/articles/PMC7912042/ /pubmed/33514009 http://dx.doi.org/10.3390/pharmaceutics13020171 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ruponen, Marika Kettunen, Konsta Santiago Pires, Monica Laitinen, Riikka Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs |
title | Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs |
title_full | Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs |
title_fullStr | Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs |
title_full_unstemmed | Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs |
title_short | Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs |
title_sort | co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912042/ https://www.ncbi.nlm.nih.gov/pubmed/33514009 http://dx.doi.org/10.3390/pharmaceutics13020171 |
work_keys_str_mv | AT ruponenmarika coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs AT kettunenkonsta coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs AT santiagopiresmonica coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs AT laitinenriikka coamorphousformulationsoffurosemidewitharginineandpglycoproteininhibitordrugs |